If New Metal Legs Let You Run 20 Miles/Hour, Would You Amputate Your Own?

If New Metal Legs Let You Run 20 Miles/Hour, Would You Amputate Your Own?

A patient with below-knee AMI amputation walks up the stairs.

(Photo credit: Matthew Orr, STAT News)


Keep Reading Keep Reading
Tyler Clites
Tyler Clites builds human cyborgs. After graduating from Harvard in 2014 with a B.S. in Biomedical and Mechanical Engineering, Tyler earned his PhD in 2018 from the Harvard/MIT program in Health Sciences and Technology. As a postdoc in the Biomechatronics Group (Professor Hugh Herr, MIT Media Lab), his current research focuses on the development of novel techniques for limb amputation surgery, with the goal of improving the neural and mechanical interfaces between persons with amputation and their prosthetic devices. He is pursuing a career in academia, where he hopes to explore applications in which surgical and mechatronic design can be leveraged together in new bionic systems for physical rehabilitation and human augmentation.
Get our top stories twice a month
Follow us on
The Friday Five: Soon Band-Aids Could Be AIs

In this week's Friday Five, research on a "smart" bandage for wounds, a breakthrough in fighting inflammation, the pros and cons of a new drug for Alzheimer's, benefits of the Mediterranean diet with a twist, and we've learned to recycle a plastic that was un-recyclable.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.

Sexually Transmitted Infections are on the rise. This drug could stop them.

Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.

Adobe Stock

Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.

It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.